ACE Bio collaborates with PATH on ETEC vacc

ACE BioSciences, a Danish biotechnology company focused on vaccines for infectious diseases, has entered into a research collaboration with PATH, an international, non-profit, non-governmental organization, to develop temperature-stable enterotoxigenic Escherichia coli vaccine formulations.

Under the terms of the agreement, funded under PATH's Enteric Vaccine Initiative, ACE BioSciences will collaborate with PATH's vaccine stabilization project team to develop dry and temperature-stable ETEC vaccine candidates. The pilot studies will utilize ACE527, ACE BioSciences' live, whole-cell oral vaccine candidate which comprises three attenuated ETEC strains and represents the culmination of a development program, which has already demonstrated safety and immunogenicity in five clinical trials.

In addition to providing its ETEC strains, ACE BioSciences will contribute its proprietary knowledge on optimized growth and freeze drying methods and analytical assays for the ETEC strains and give technical support. All parties will share the results of the work.